吉西他滨
胰腺癌
曲美替尼
裸鼠
联合疗法
癌症研究
脱氧胞苷
癌症
医学
化疗
肿瘤科
内科学
生物
药理学
MAPK/ERK通路
生物化学
激酶
作者
Koji Kawaguchi,Kentaro Igarashi,Thinzar M. Lwin,Kentaro Miyake,Tasuku Kiyuna,Ho Kyoung Hwang,Takashi Murakami,Jonathan C. DeLong,Shree Ram Singh,Bryan M. Clary,Michael Bouvet,Michiaki Unno,Robert M. Hoffman
出处
期刊:Tissue & Cell
[Elsevier]
日期:2018-06-01
卷期号:52: 124-128
被引量:18
标识
DOI:10.1016/j.tice.2018.05.003
摘要
Pancreatic cancer is resistant to treatment and needs precision individualized therapy to improve the outcome of this disease. Previously, we demonstrated that trametinib (TRA), a MEK inhibitor, could inhibit a pancreatic cancer patient-derived orthotopic xenograft (PDOX). In the present study, we show that gemcitabine (GEM) in combination with TRA was more effective than TRA alone. We implanted a patient pancreatic cancer orthotopically in the pancreatic tail of nude mice to establish the PDOX model. After seven weeks of tumor growth, we divided 32 pancreatic-cancer PDOX nude mice into 4 groups of eight: untreated control; GEM (once a week for 2 weeks); TRA (14 consecutive days); GEM + TRA (GEM: once a week for 2 weeks, TRA:14 consecutive days). We found that treated mice on day 14 had significantly reduced tumor volume in comparison to untreated control. TRA and the combination of GEM + TRA therapy significantly inhibited tumor development in comparison to GEM alone. However, GEM + TRA inhibited the PDOX tumor growth significantly greater than TRA alone. These results suggest the clinical potential of the combination of TRA and GEM for pancreatic cancer.
科研通智能强力驱动
Strongly Powered by AbleSci AI